Safety and efficacy of depatuxizumab mafodotin in Japanese patients with malignant glioma: A nonrandomized, phase 1/2 trial.

MLA

Narita, Yoshitaka, et al. “Safety and Efficacy of Depatuxizumab Mafodotin in Japanese Patients with Malignant Glioma: A Nonrandomized, Phase 1/2 Trial.” Cancer Science, vol. 112, no. 12, Dec. 2021, pp. 5020–33. EBSCOhost, https://doi.org/10.1111/cas.15153.

APA

Narita, Y., Muragaki, Y., Kagawa, N., Asai, K., Nagane, M., Matsuda, M., Ueki, K., Kuroda, J., Date, I., Kobayashi, H., Kumabe, T., Beppu, T., Kanamori, M., Kasai, S., Nishimura, Y., Xiong, H., Ocampo, C., Yamada, M., & Mishima, K. (2021). Safety and efficacy of depatuxizumab mafodotin in Japanese patients with malignant glioma: A nonrandomized, phase 1/2 trial. Cancer Science, 112(12), 5020–5033. https://doi.org/10.1111/cas.15153

Chicago

Narita, Yoshitaka, Yoshihiro Muragaki, Naoki Kagawa, Katsunori Asai, Motoo Nagane, Masahide Matsuda, Keisuke Ueki, et al. 2021. “Safety and Efficacy of Depatuxizumab Mafodotin in Japanese Patients with Malignant Glioma: A Nonrandomized, Phase 1/2 Trial.” Cancer Science 112 (12): 5020–33. doi:10.1111/cas.15153.